Aspen Aerogels Tops Q3 Outlook, but Q4 Revenue Guidance Falls to $60-75M
ASPN has more than doubled off its 52-week low of $2.3.
Summary
Aspen Aerogels beat its Q3 revenue and Adjusted EBITDA outlook ($85.2M and $19.8M), but guided Q4 revenue down to $60M-$75M with another net loss as East Providence repair costs persist. The board also added former Citadel analyst Stacy Nieuwoudt as a director.
Key Events · Earnings and Guidance · ASPN
-
Q3 Beats High End of Outlook
Revenue of $85.2M rose 71% quarter-over-quarter, and Adjusted EBITDA of $19.8M (23% margin) came in above the high end of guidance.
-
Q4 Guidance Steps Down
Q4 revenue is guided to $60M-$75M, with a net loss of $11M-$8M and Adjusted EBITDA of $5M-$13M, excluding an estimated $5M-$10M of East Providence incident costs.
-
Incident Costs Drive GAAP Loss
The $10.4M net loss ($0.13 per share) included $15.1M of East Providence incident-related costs and a $4.6M loss on disposal of Statesboro assets; adjusted net income was $9.3M ($0.11 per share).
-
East Providence Restart in 1H 2027
The facility remains on track for completion in the first half of 2027; until then, the company is sourcing product externally at incremental cost.
Analysis · ASPN · Trade & Services
The headline beat is real: Q3 revenue of $85.2M and Adjusted EBITDA of $19.8M both cleared the high end of guidance. What matters more is the Q4 outlook, which calls for revenue of $60M-$75M — a step down from the record quarter — and another net loss of $11M-$8M as East Providence repair costs of $5M-$10M keep weighing. The quarter's GAAP loss stemmed from $15.1M of incident-related costs and a $4.6M write-down of Statesboro assets, not from the core business, which posted a 41% adjusted gross margin. Cash fell to $146.5M from $158.6M at year-end, and the East Providence facility will not return to full production until the first half of 2027 — that restart is the single biggest swing factor for 2027 numbers. Separately, the board added Stacy Nieuwoudt, a former Citadel energy analyst, as an independent director.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASPN was trading at $4.84 on NYSE in the Trade & Services sector, with a market capitalization of approximately $398.3M. The 52-week trading range was $2.30 to $8.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.